Mehmet Hilmi Doğu

The outcome of COVID‐19 in patients with hematological malignancy

Tuğçe Nur Yiğenoğlu, Naim Ata, Fevzi Altuntaş et al. · Journal of Medical Virology · 2020 · 134 citations · Full text

Medicine, Hematology, Oncology +16

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Hüseyin Saffet Beköz, Nuri Karadurmuş, S. Paydaş et al. · Annals of Oncology · 2017 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Convalescent plasma therapy in patients with COVID-19

Fevzi Altuntaş, Naim Ata, Tuğçe Nur Yiğenoğlu et al. · Transfusion and Apheresis Science · 2020 · 65 citations · Full text

Veterinary Medicine, Clinical Sciences, Infectious Diseases +7

Therapeutic plasma exchange in patients with neurological diseases: Multicenter retrospective analysis

Muzaffer Keklık, Mehmet Şencan, Alî Keskin et al. · Transfusion and Apheresis Science · 2013 · 51 citations

Medicine, Neurology, Neurosurgery +7

Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

Semih Başçı, Naim Ata, Fevzi Altuntaş et al. · Journal of Oncology Pharmacy Practice · 2020 · 40 citations · Full text

Medicine, Hematology, Oncology +13